Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.50 |
| ▸ | CASR | P41180 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13997823 | 0.84 | ALDH1A1 (0.46) | ALDH1A1HTTSMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL3348575 | 0.82 | ALDH1A1 (0.55) | ALDH1A1HTTSMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL2205978 | 0.80 | MTNR1A (0.65) | ALDH1A1HTTSMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL3507239 | 0.80 | LAP3 (0.49) | — | |
| SCHEMBL28034591 | 0.79 | TAAR1 (0.55) | TAAR1MEN1KMT2ABCHE | |
| SCHEMBL13849891 | 0.79 | TAAR1 (0.58) | TAAR1 | |
| SCHEMBL13849941 | 0.79 | TAAR1 (0.58) | TAAR1 | |
| SCHEMBL14402407 | 0.79 | TAAR1 (0.58) | TAAR1 | |
| SCHEMBL5069135 | 0.78 | MTNR1A (0.62) | ALDH1A1HTTMTNR1AMTNR1BCASR | |
| SCHEMBL13725463 | 0.78 | MTNR1A (0.79) | ALDH1A1HTTSMN1; SMN2MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318947-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | ALDH1A1 4166/4885HTT 2591/4885SMN1; SMN2 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.